Aligos Therapeutics (ALGS) EBT (2019 - 2026)

Aligos Therapeutics (ALGS) has reported EBT for 8 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 108.34% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at -$72.7 million (up 1.48% YoY), and the FY2025 full-year result was -$23.9 million, up 81.76% from the prior year.
• EBT grew to $1.3 million in Q2 2026 per ALGS's latest filing, from -$22.7 million in the prior quarter.
• Across five years, EBT topped out at $43.1 million in Q1 2025 and bottomed at -$82.1 million in Q4 2024.
• Historically, EBT has averaged -$19.9 million across 5 years, with a median of -$19.9 million in 2022.
• The widest YoY moves for EBT: up 223.8% in 2025, down 398.63% in 2025.
• Over 5 years, EBT stood at -$21.8 million in 2022, then dropped by 27.87% to -$27.9 million in 2023, then tumbled by 194.12% to -$82.1 million in 2024, then surged by 75.83% to -$19.9 million in 2025, then jumped by 106.58% to $1.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $1.3 million, -$22.7 million, and -$19.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.